Estados Unidos · Bolsa y Finanzas · Yahoo Finance

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

Publicado por Yahoo Finance · Estados Unidos hace 10 h

Johnson & Johnson (NYSE: JNJ) reported new Phase 3 results for oral peptide ICOTYDE in plaque psoriasis at the 2026 EADV Congress. The oral IL-23 inhibitor showed sustained skin…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

También te puede interesar

Federal judge calls Flock ‘indiscriminate mass surveillance’

Key deals this week: Onsemi, Mattel, Nebius, Advanced Micro Devices, and more

OpenAI leader who quit says he can do more for safety from outside the company

Iran Is Losing Some of Its Leverage Over the Strait of Hormuz

High mortgage rates are trapping homeowners in place, and making renovations harder to afford

U.S. debt is increasingly at the mercy of the market as interest costs surge while elections add more risk to the debt ceiling, ratings agency warns

Johnson & Johnson (JNJ) Reports Sustained Phase 3 Skin Clearance For ICOTYDE

Compartir

También te puede interesar

Federal judge calls Flock ‘indiscriminate mass surveillance’

Key deals this week: Onsemi, Mattel, Nebius, Advanced Micro Devices, and more

OpenAI leader who quit says he can do more for safety from outside the company

Iran Is Losing Some of Its Leverage Over the Strait of Hormuz

High mortgage rates are trapping homeowners in place, and making renovations harder to afford

U.S. debt is increasingly at the mercy of the market as interest costs surge while elections add more risk to the debt ceiling, ratings agency warns